| abstract |
Congestive heart failure (CHF) due to hypertension (HTN) or non-insulin dependent diabetes (type II diabetes) (NIDDM), atherosclerotic peripheral vascular disease (ASPVD) and chronic obstructive pulmonary disease due to HTN or NIDDM More than 40 common diseases other than emphysema (COPD) are associated with the ACE D / D genotype, as well as responding to appropriate tissue-inhibiting doses of ACE inhibitors (eg, quinapril). We have now succeeded in treating several of these diseases with higher than normal doses of ACE inhibitors, especially hydrophobic ACE inhibitors, with good outcomes. ACE inhibitors have also been found to be useful in suppressing apoptosis and aging in general. The doses used are generally higher than quinapril 40-80 mg / day, i.e. up to 1 mg / kg / day, in "typical" patients weighing 80 kg. 80 mg tablets, controlled and / or sustained release formulations and second active agents (eg diuretics) as formulations of ACE inhibitors corresponding to these high doses to prevent fluid retention and congestive heart failure in patients with renal failure Alternatively, new formulations such as formulations containing compounds (for example, furosemide 20 mg / day (creatinine <2.5 mg / dl) or furosemide 40 mg / day (creatinine> 2.5 mg / dl)) were developed. ACE inhibitors may be used in combination with angiotensin receptor blockers. |